MedPage Today on MSN21h
FDA Expands Guselkumab Approval to Crohn's DiseaseThe FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease ...
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease ...
The IL-23 pathway is already targeted by various injectable antibody-based drugs, including AbbVie's own Skyrizi (risankizumab) – which is FDA-approved for plaque psoriasis, psoriatic arthritis ...
J&J’s Janssen unit and partner Protagonist Therapeutics hope to show that the peptide drug can be an alternative to injectable biologics ... AbbVie’s Skyrizi (risankizumab), and Sun Pharma ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
After hours: 19 March at 19:50:42 GMT-4 Loading Chart for ABBV ...
Pre-market: 8:53:50 am GMT-4 Loading Chart for ABBV ...
The following biologics may be given by injection or infusion: Psoriasis can have serious health complications, including psoriatic arthritis, which affects the joints in up to 30% of people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback